Carlos is a 45-year-old male with moderate-to-severe plaque psoriasis diagnosed 5 years ago. He has no significant comorbidities and no known drug allergies. He has been managed with topical therapies but now requires systemic treatment due to worsening skin involvement. He is considering starting either methotrexate or risankizumab. His current medications include only occasional acetaminophen for headaches. Carlos is concerned about treatment effectiveness and long-term skin clearance.

Question: Based on the IMMbrace study findings, which systemic therapy would you recommend to Carlos to achieve the highest likelihood of skin clearance at 28 weeks?

Ana is a 52-year-old female with moderate-to-severe plaque psoriasis and a history of mild liver enzyme elevation. She is currently not on systemic therapy but requires initiation of treatment. She is concerned about potential adverse effects, especially hepatotoxicity. Her current medications include lisinopril for hypertension and no known drug allergies.

Question: Considering the IMMbrace study safety data, which statement best describes the safety profile of risankizumab compared to methotrexate?

João is a 60-year-old male with moderate-to-severe plaque psoriasis who started risankizumab therapy 6 months ago. He achieved significant skin clearance and is now concerned about the durability of treatment benefits and the need for ongoing therapy. He asks about the expected long-term efficacy and safety of risankizumab.

Question: What information from the IMMbrace study can you provide João regarding the long-term use of risankizumab?